Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments
- PMID: 9631086
- DOI: 10.1038/nbt1096-1239
Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments
Abstract
Disulfide-stabilized Fv fragments of antibodies (dsFv) are molecules in which the VH-VL heterodimer is stabilized by an interchain disulfide bond engineered between structurally conserved framework positions distant from complementarity-determining regions (CDRs). This method of stabilization is applicable for the stabilization of many antibody Fvs and has also been applied to a T-cell receptor Fv. A summary of the design strategy, and the construction and production of various dsFvs and dsFv-fusion proteins is presented. Included in the discussion are the biochemical features of dsFvs in comparison with scFvs, the effect of disulfide stabilization on Fv binding and activity, and various applications of dsFvs and dsFv-immunotoxins for tumor imaging and the treatment of solid tumors in animal models.
Similar articles
-
Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.Clin Cancer Res. 1996 Feb;2(2):245-52. Clin Cancer Res. 1996. PMID: 9816166 Review.
-
Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv.Protein Eng. 1994 May;7(5):697-704. doi: 10.1093/protein/7.5.697. Protein Eng. 1994. PMID: 8073039
-
Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.Cancer Res. 1994 May 15;54(10):2714-8. Cancer Res. 1994. PMID: 8168102
-
Disulfide stabilization of antibody Fv: computer predictions and experimental evaluation.Protein Eng. 1995 Dec;8(12):1323-31. doi: 10.1093/protein/8.12.1323. Protein Eng. 1995. PMID: 8869646
-
Pharmacokinetics and biodistribution of genetically-engineered antibodies.Q J Nucl Med. 1998 Dec;42(4):225-41. Q J Nucl Med. 1998. PMID: 9973838 Review.
Cited by
-
Designing immunotoxins for cancer therapy.Immunol Res. 2002;25(2):177-91. doi: 10.1385/IR:25:2:177. Immunol Res. 2002. PMID: 11999171 Review.
-
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds.J Biol Eng. 2021 Jun 29;15(1):18. doi: 10.1186/s13036-021-00272-7. J Biol Eng. 2021. PMID: 34187511 Free PMC article.
-
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.Protein Eng Des Sel. 2012 Oct;25(10):571-80. doi: 10.1093/protein/gzs064. Epub 2012 Sep 13. Protein Eng Des Sel. 2012. PMID: 22976197 Free PMC article.
-
Targeting malignant B cells with an immunotoxin against ROR1.MAbs. 2012 May-Jun;4(3):349-61. doi: 10.4161/mabs.19870. Epub 2012 Apr 26. MAbs. 2012. PMID: 22531447 Free PMC article.
-
The making of bispecific antibodies.MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307. MAbs. 2017. PMID: 28071970 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources